The DIAPH3 Knockout Huh-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of Huh-7 hepatocellular carcinoma cells with targeted disruption of the DIAPH3 gene. This knockout model introduces a loss-of-function for diaphanous-related formin 3, enabling comprehensive investigation of DIAPH3-dependent actin dynamics and signaling in a human liver cancer background. The polyclonal format captures a spectrum of editing events, providing a versatile tool for functional genomics and phenotypic screening without clonal selection biases. Researchers can use this population to study DIAPH3 biology in a genetically heterogeneous context that more closely mirrors the diversity of tumor cell populations.
The parental Huh-7 cell line is a well-established human hepatocellular carcinoma epithelial line originally derived from a liver tumor. It retains key hepatocyte characteristics and is extensively used in cancer biology, including investigations of oncogenic signaling, drug metabolism, and metastatic mechanisms. Huh-7 cells express many liver-specific markers and are susceptible to common hepatocellular carcinoma drivers, making them a relevant host for dissecting gene function in hepatic malignancies. Their adherent growth and robust migratory capacity facilitate standardized assays for cytoskeletal and invasion phenotypes, making this knockout derivative a powerful extension for liver cancer and migration research.
DIAPH3 is a member of the formin family of actin nucleators that promotes the assembly of unbranched actin filaments downstream of Rho GTPases such as RhoA, Rac1, and CDC42. It interacts directly with angiomotin (AMOT) and profilin to regulate actin polymerization at filopodia and lamellipodia, thereby controlling cell migration and cytokinesis. DIAPH3 functions within the RhoA/ROCK/DIAPH3/actin cascade and collaborates with AMOT to modulate Hippo pathway activity, linking cytoskeletal dynamics to transcriptional regulation. It is transcriptionally regulated by serum response factor (SRF) and receives inputs from PI3K/AKT signaling, placing it at the intersection of mechanical and growth factor cues. Together, these interactions position DIAPH3 as a critical node in actin cytoskeleton regulation and cell motility.
In the context of hepatocellular carcinoma, DIAPH3 has been implicated in cancer cell invasion and metastasis, processes that rely heavily on actin remodeling. Loss of DIAPH3 in Huh-7 cells is expected to impair filopodia formation, directed migration, and invasion, thereby providing a model to dissect the cytoskeletal underpinnings of liver tumor dissemination. Furthermore, the interaction between DIAPH3 and AMOT connects actin dynamics to Hippo pathway signaling, which is frequently dysregulated in hepatocellular carcinoma. Consequently, these knockout cells enable the study of how DIAPH3-mediated actin reorganization influences Hippo-dependent growth control and metastatic potential in a liver cancer setting, offering insight into potential therapeutic vulnerabilities.
This knockout product is suited for a wide array of experimental applications. Researchers can employ western blotting to confirm DIAPH3 protein depletion, immunofluorescence to visualize F-actin architecture, and RT-qPCR to assess mRNA knockdown. Functional assays such as wound healing and transwell migration provide quantitative measures of cell motility, while co-immunoprecipitation with AMOT examines the DIAPH3-AMOT interaction. These cells are also valuable for cytoskeletal drug screening targeting actin dynamics or Rho GTPase signaling in hepatocellular carcinoma. By combining CRISPR/Cas9-mediated gene disruption with a cancer-relevant host, the DIAPH3 Knockout Huh-7 Polyclonal Cells offer a robust platform for advancing metastasis research. For additional information, please contact Ascent Research.
